NO20041882L - Fremgangsmater for behandling av okulare neovaskulaere sykdommer. - Google Patents
Fremgangsmater for behandling av okulare neovaskulaere sykdommer.Info
- Publication number
- NO20041882L NO20041882L NO20041882A NO20041882A NO20041882L NO 20041882 L NO20041882 L NO 20041882L NO 20041882 A NO20041882 A NO 20041882A NO 20041882 A NO20041882 A NO 20041882A NO 20041882 L NO20041882 L NO 20041882L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- methods
- ocular neovascular
- neovascular diseases
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33230401P | 2001-11-09 | 2001-11-09 | |
PCT/US2002/035986 WO2003039404A2 (en) | 2001-11-09 | 2002-11-08 | Methods for treating ocular neovascular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20041882L true NO20041882L (no) | 2004-05-07 |
Family
ID=23297643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20041882A NO20041882L (no) | 2001-11-09 | 2004-05-07 | Fremgangsmater for behandling av okulare neovaskulaere sykdommer. |
Country Status (26)
Country | Link |
---|---|
US (3) | US20030171320A1 (no) |
EP (1) | EP1441743A4 (no) |
JP (1) | JP2005511576A (no) |
KR (1) | KR20050044372A (no) |
CN (1) | CN1582156A (no) |
AP (1) | AP1750A (no) |
AR (1) | AR037307A1 (no) |
BR (1) | BR0213975A (no) |
CA (1) | CA2464007A1 (no) |
CR (1) | CR7330A (no) |
EA (1) | EA006746B1 (no) |
EC (1) | ECSP045098A (no) |
GE (1) | GEP20063755B (no) |
HR (1) | HRP20040406A2 (no) |
IL (1) | IL161327A0 (no) |
IS (1) | IS7215A (no) |
MA (1) | MA27145A1 (no) |
MX (1) | MXPA04004363A (no) |
NO (1) | NO20041882L (no) |
OA (1) | OA12720A (no) |
PL (1) | PL371929A1 (no) |
RS (1) | RS35404A (no) |
TN (1) | TNSN04081A1 (no) |
TW (1) | TWI260327B (no) |
WO (1) | WO2003039404A2 (no) |
ZA (1) | ZA200402753B (no) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60135633D1 (de) | 2000-02-10 | 2008-10-16 | Massachusetts Eye & Ear Infirm | Photodynamische therapie zur behandlung von augenerkrankungen |
US6936043B2 (en) * | 2001-11-13 | 2005-08-30 | Minu, Llc | Method to treat age-related macular degeneration |
US6942655B2 (en) * | 2001-11-13 | 2005-09-13 | Minu, Llc | Method to treat age-related macular degeneration |
CA2530166A1 (en) * | 2003-03-07 | 2004-09-23 | Randolph D. Glickman | Antibody-targeted photodynamic therapy |
CL2004001996A1 (es) * | 2003-08-08 | 2005-05-06 | Eyetech Pharmaceuticals Inc | Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion. |
PL1660057T3 (pl) | 2003-08-27 | 2012-10-31 | Ophthotech Corp | Terapia łączona do leczenia zaburzeń związanych z neowaskularyzacją gałki ocznej |
US7575321B2 (en) * | 2003-10-30 | 2009-08-18 | Welch Allyn, Inc. | Apparatus and method of diagnosis of optically identifiable ophthalmic conditions |
WO2005044817A1 (en) | 2003-11-05 | 2005-05-19 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
WO2005072701A1 (en) | 2004-01-20 | 2005-08-11 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
WO2005084412A2 (en) * | 2004-03-05 | 2005-09-15 | Archemix Corp. | Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics |
US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
PL2484365T3 (pl) * | 2004-06-04 | 2014-03-31 | Scripps Research Inst | Kompozycje i sposoby leczenia chorób neowaskularnych |
US7785784B2 (en) * | 2004-07-23 | 2010-08-31 | Eyetech, Inc. | Detection of oligonucleotides by dual hybridization |
JP2006056807A (ja) * | 2004-08-18 | 2006-03-02 | Konica Minolta Medical & Graphic Inc | 光線力学療法製剤 |
PT1802334E (pt) * | 2004-10-21 | 2012-11-28 | Genentech Inc | Método para tratamento de doenças neovasculares intraoculares |
AU2012200865A1 (en) * | 2004-10-21 | 2012-03-29 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
US20060111423A1 (en) * | 2004-10-26 | 2006-05-25 | Zeligs Michael A | Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease |
AU2005309854A1 (en) * | 2004-11-24 | 2006-06-01 | Therakine Ltd. | An implant for intraocular drug delivery |
US20060134176A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
US20060134174A1 (en) * | 2004-12-22 | 2006-06-22 | Bausch & Lomb Incorporated | Pharmaceutical delivery system and method of use |
US20060134175A1 (en) * | 2004-12-22 | 2006-06-22 | Stephen Bartels | Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use |
DK1848431T3 (en) | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
BRPI0609432A2 (pt) * | 2005-03-21 | 2010-04-06 | Macusight Inc | sistemas de distribuição de fármacos para tratamento de doenças ou condições |
US20060293270A1 (en) * | 2005-06-22 | 2006-12-28 | Adamis Anthony P | Methods and compositions for treating ocular disorders |
CN101316584A (zh) * | 2005-09-27 | 2008-12-03 | 北海道公立大学法人札幌医科大学 | 用于预防及治疗由血管通透性亢进引起的眼病的医药 |
US8168584B2 (en) * | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
CA2622312A1 (en) * | 2006-01-30 | 2007-08-02 | (Osi) Eyetech, Inc. | Combination therapy for the treatment of neovascular disorders |
WO2007092620A2 (en) * | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
US20070248646A1 (en) * | 2006-02-16 | 2007-10-25 | Ali Hafezi-Moghadam | Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage |
US20070218007A1 (en) * | 2006-03-17 | 2007-09-20 | Allergan, Inc. | Ophthalmic visualization compositions and methods of using same |
KR101520408B1 (ko) | 2006-03-23 | 2015-05-14 | 산텐 세이야꾸 가부시키가이샤 | 혈관 투과성-관련 질환 또는 상태를 위한 제형 및 방법 |
SI2944306T1 (sl) * | 2006-06-16 | 2021-04-30 | Regeneron Pharmaceuticals, Inc. | Formulacije antagonista VEGF, primerne za intravitrealno dajanje |
US8668676B2 (en) * | 2006-06-19 | 2014-03-11 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
US20080097335A1 (en) * | 2006-08-04 | 2008-04-24 | Allergan, Inc. | Ocular implant delivery assemblies |
WO2008103320A1 (en) * | 2007-02-16 | 2008-08-28 | Novacea, Inc. | Methods of treating ophthalmic disorders with anthraquinones |
JP2008308488A (ja) * | 2007-05-11 | 2008-12-25 | Santen Pharmaceut Co Ltd | 非麦角系の選択的d2受容体アゴニストを有効成分として含有する後眼部疾患の予防又は治療剤 |
US9125807B2 (en) * | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
ES2830024T3 (es) * | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
US8530189B2 (en) * | 2008-10-16 | 2013-09-10 | Kathleen Cogan Farinas | Sustained drug delivery system |
CN102215875B (zh) * | 2008-10-16 | 2014-08-06 | 凯瑟琳·科根·法瑞纳斯 | 持续药物递送系统 |
EP2379109B1 (en) * | 2008-12-16 | 2020-10-07 | Bausch Health Companies Inc. | Combination of photodynamic therapy and anti-vegf agents in the treatment of unwanted choroidal neovasculature |
US8545554B2 (en) * | 2009-01-16 | 2013-10-01 | Allergan, Inc. | Intraocular injector |
EP2393513B1 (en) | 2009-02-06 | 2016-10-19 | The General Hospital Corporation | Methods of treating vascular lesions |
US8829020B2 (en) | 2009-07-16 | 2014-09-09 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
AU2011206104A1 (en) * | 2010-01-14 | 2012-07-12 | Nagoya City University | Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability |
WO2012047587A2 (en) * | 2010-09-27 | 2012-04-12 | Serrata, Llc | Mdm2 inhibitors for treatment of ocular conditions |
CN103533950A (zh) | 2011-01-13 | 2014-01-22 | 瑞泽恩制药公司 | Vegf拮抗剂在治疗血管生成眼病中的用途 |
CN103391782A (zh) | 2011-02-02 | 2013-11-13 | 公立大学法人名古屋市立大学 | 用于预防或治疗伴有眼内血管新生及/或眼内血管渗透性过高的疾病的药物 |
KR101303920B1 (ko) * | 2011-04-26 | 2013-09-05 | 서울대학교산학협력단 | 프로토포르피린 IX 구조를 갖는 화합물을 포함하는, 저산소상태 유도성인자1α 또는 혈관내피세포성장인자 과다 발현으로 기인하는 질병의 예방 및 치료에 유용한 조성물 |
TW201406707A (zh) * | 2012-05-04 | 2014-02-16 | Acucela Inc | 用以治療糖尿病性視網膜病變及其他眼部疾病之方法 |
AU2013100070B4 (en) * | 2012-07-03 | 2013-04-04 | Novartis Ag | Use of device |
CN103721257B (zh) * | 2012-10-16 | 2016-12-21 | 无锡兆真辐射技术有限公司 | 光敏素催化分解过氧化氢系列药物 |
ES2879430T3 (es) | 2012-11-15 | 2021-11-22 | Apellis Pharmaceuticals Inc | Análogos de compstatina de acción prolongada y composiciones y métodos relacionados |
WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
RU2527360C1 (ru) * | 2013-04-23 | 2014-08-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения Российской Федерации | Способ комбинированного лечения ретиноваскулярного макулярного отека |
JP2016531901A (ja) | 2013-07-12 | 2016-10-13 | オプソテック コーポレイションOphthotech Corporation | 眼科症状を処置するまたは予防するための方法 |
CA2934462A1 (en) * | 2013-12-24 | 2015-07-02 | Novelmed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
RU2770099C2 (ru) | 2015-10-07 | 2022-04-14 | Апеллис Фармасьютикалс, Инк. | Схемы введения |
CN114712497B (zh) | 2015-12-03 | 2024-03-22 | 雷杰纳荣制药公司 | 抗vegf剂在制备用于治疗新生血管性年龄相关性黄斑变性患者的药物中的用途 |
SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
MX2019012033A (es) | 2017-04-07 | 2019-12-05 | Apellis Pharmaceuticals Inc | Regímenes de dosificación y composiciones y métodos relacionados. |
DE102017008721A1 (de) | 2017-09-16 | 2019-03-21 | protectismundi GmbH | Verfahren und Vorrichtung zur Hochhausbrandbekämfpung |
SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
WO2019210097A1 (en) * | 2018-04-25 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Aptamers with stability, potency or half-life for enhanced safety and efficacy |
US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
CN113101530B (zh) * | 2021-04-14 | 2022-09-30 | 中国人民解放军陆军特色医学中心 | 一种通过无线充电激活玻璃体腔植入性发光二极管的系统 |
KR20240121668A (ko) | 2023-02-01 | 2024-08-09 | 아주대학교산학협력단 | 염증성 눈질환의 예방 및 치료용 조성물 |
CN118108804B (zh) * | 2024-04-26 | 2024-06-25 | 山东大学 | 一种缺氧敏感功能化修饰的抗血管生成多肽、纳米胶束材料及其制备方法与应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
US5342348A (en) * | 1992-12-04 | 1994-08-30 | Kaplan Aaron V | Method and device for treating and enlarging body lumens |
US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
WO1995024930A1 (en) * | 1994-03-14 | 1995-09-21 | Massachusetts Eye & Ear Infirmary | Use of green porphyrins in ocular diagnosis and therapy |
US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
JP3845469B2 (ja) * | 1996-02-21 | 2006-11-15 | 明治製菓株式会社 | 眼底の新生血管の閉塞に用いる投与剤 |
US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
AU733674B2 (en) * | 1996-10-25 | 2001-05-24 | Gilead Sciences, Inc. | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
US6123923A (en) * | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US6117862A (en) * | 1998-10-09 | 2000-09-12 | Qlt, Inc. | Model and method for angiogenesis inhibition |
WO2001051087A2 (en) * | 2000-01-12 | 2001-07-19 | Light Sciences Corporation | Novel treatment for eye disease |
DE60135633D1 (de) * | 2000-02-10 | 2008-10-16 | Massachusetts Eye & Ear Infirm | Photodynamische therapie zur behandlung von augenerkrankungen |
MXPA01011346A (es) * | 2000-03-10 | 2002-09-02 | Insite Vision Inc | Metodos y composiciones para el tratamiento y prevencion de padecimientos oftalmicos del segmento posterior. |
EP1265636A2 (en) * | 2000-03-24 | 2002-12-18 | Novartis AG | Improved treatment of neovascularization |
US6936043B2 (en) * | 2001-11-13 | 2005-08-30 | Minu, Llc | Method to treat age-related macular degeneration |
US20060258629A1 (en) * | 2002-10-18 | 2006-11-16 | Freeman William R | Photodynamic therapy for ocular neovascularization |
-
2002
- 2002-11-08 MX MXPA04004363A patent/MXPA04004363A/es not_active Application Discontinuation
- 2002-11-08 AP APAP/P/2004/003026A patent/AP1750A/en active
- 2002-11-08 WO PCT/US2002/035986 patent/WO2003039404A2/en active Application Filing
- 2002-11-08 KR KR1020047006990A patent/KR20050044372A/ko not_active Application Discontinuation
- 2002-11-08 OA OA1200400130A patent/OA12720A/en unknown
- 2002-11-08 IL IL16132702A patent/IL161327A0/xx unknown
- 2002-11-08 TW TW091132890A patent/TWI260327B/zh not_active IP Right Cessation
- 2002-11-08 EP EP02802885A patent/EP1441743A4/en not_active Withdrawn
- 2002-11-08 RS YU35404A patent/RS35404A/sr unknown
- 2002-11-08 JP JP2003541500A patent/JP2005511576A/ja active Pending
- 2002-11-08 US US10/291,091 patent/US20030171320A1/en not_active Abandoned
- 2002-11-08 CN CNA028219562A patent/CN1582156A/zh active Pending
- 2002-11-08 PL PL02371929A patent/PL371929A1/xx not_active Application Discontinuation
- 2002-11-08 BR BR0213975-8A patent/BR0213975A/pt not_active IP Right Cessation
- 2002-11-08 EA EA200400518A patent/EA006746B1/ru not_active IP Right Cessation
- 2002-11-08 GE GE5563A patent/GEP20063755B/en unknown
- 2002-11-08 CA CA002464007A patent/CA2464007A1/en not_active Abandoned
- 2002-11-11 AR ARP020104328A patent/AR037307A1/es unknown
-
2004
- 2004-02-25 US US10/786,491 patent/US20040167091A1/en not_active Abandoned
- 2004-04-07 IS IS7215A patent/IS7215A/is unknown
- 2004-04-08 ZA ZA200402753A patent/ZA200402753B/en unknown
- 2004-04-29 MA MA27662A patent/MA27145A1/fr unknown
- 2004-04-30 CR CR7330A patent/CR7330A/es not_active Application Discontinuation
- 2004-05-07 HR HR20040406A patent/HRP20040406A2/hr not_active Application Discontinuation
- 2004-05-07 EC EC2004005098A patent/ECSP045098A/es unknown
- 2004-05-07 TN TNP2004000081A patent/TNSN04081A1/fr unknown
- 2004-05-07 NO NO20041882A patent/NO20041882L/no not_active Application Discontinuation
-
2006
- 2006-07-24 US US11/491,818 patent/US20070027101A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA04004363A (es) | 2005-05-16 |
CA2464007A1 (en) | 2003-05-15 |
ECSP045098A (es) | 2004-07-23 |
EP1441743A4 (en) | 2009-02-25 |
AR037307A1 (es) | 2004-11-03 |
EA006746B1 (ru) | 2006-04-28 |
IS7215A (is) | 2004-04-07 |
KR20050044372A (ko) | 2005-05-12 |
BR0213975A (pt) | 2005-05-10 |
AP1750A (en) | 2007-06-23 |
WO2003039404A2 (en) | 2003-05-15 |
TNSN04081A1 (fr) | 2006-06-01 |
US20030171320A1 (en) | 2003-09-11 |
CN1582156A (zh) | 2005-02-16 |
US20070027101A1 (en) | 2007-02-01 |
GEP20063755B (en) | 2006-02-27 |
WO2003039404A3 (en) | 2004-02-12 |
PL371929A1 (en) | 2005-07-11 |
OA12720A (en) | 2006-06-27 |
IL161327A0 (en) | 2004-09-27 |
MA27145A1 (fr) | 2005-01-03 |
RS35404A (en) | 2006-10-27 |
AP2004003026A0 (en) | 2004-06-30 |
EP1441743A2 (en) | 2004-08-04 |
HRP20040406A2 (en) | 2005-02-28 |
ZA200402753B (en) | 2005-01-05 |
TWI260327B (en) | 2006-08-21 |
TW200302226A (en) | 2003-08-01 |
US20040167091A1 (en) | 2004-08-26 |
JP2005511576A (ja) | 2005-04-28 |
CR7330A (es) | 2005-06-15 |
EA200400518A1 (ru) | 2004-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20041882L (no) | Fremgangsmater for behandling av okulare neovaskulaere sykdommer. | |
NO20053077D0 (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
AP2004003002A0 (en) | azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease. | |
CY2015025I2 (el) | Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον | |
MXPA03002814A (es) | Derivados de morfolin-acetamida para el tratamiento de enfermedades inflamatorias. | |
IL159344A0 (en) | Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease | |
ATE472325T1 (de) | Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen | |
NO20040097L (no) | Kombinasjoner for behandling av inflammatoriske forstyrrelser | |
NO20043000L (no) | Et preparat for behandling av nevrocerebrovaskulaere sykdommer | |
DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
NO20035156D0 (no) | Fremgangsmåter for brönnbehandling | |
NO20052751D0 (no) | Oftalmisk preparat for behandling av okulaer hypertensjon. | |
NO20041386L (no) | Kombinasjoner for bahandling av immunoinflammatoriske forstyrrelser | |
NO20040516L (no) | Kombinasjonsterapi for behandling av kreft. | |
DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
ZA200501288B (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma. | |
NO20033803D0 (no) | Karbamat for behandling av bevegelseslidelser | |
NO20034123L (no) | Fremgangsmåte for behandling av brennstoff | |
IS7163A (is) | Aðferðir til meðhöndlunar á lungnasjúkdómi | |
DK1268482T3 (da) | Pyranoindoler til behandling af glaukom | |
NO20042476L (no) | Anvendelse av desoxypeganin for behandling av klinisk depresjon | |
NO20012612L (no) | Isonipecotamider for behandlingen av integrin-formidlede sykdommer | |
NO20030717D0 (no) | Forbindelser for behandling av avhengighetsforstyrrelser | |
ATE343387T1 (de) | S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen. | |
NO20033290D0 (no) | Pyrrolderivater for behandling av cytokinformidlede sykdommer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |